Rodeo Therapeutics snaps up $5.9 mln Series B
Seattle-based Rodeo Therapeutics Corp, a developer of small-molecule therapies to promote regeneration and repair of multiple tissue types, has secured $5.9 million in Series A funding. The investors in this round included AbbVie Ventures, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Inc., Watson Fund, L.P., WRF Capital and WuXi AppTec.
25 July 2017•1 min read
